查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984214

罕见疾病诊断市场：按检测类型、技术、疾病类型和最终用户分類的全球市场预测 – 2026-2032 年

Rare Disease Diagnostics Market by Test type, Technology, Disease Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，罕见疾病诊断市场价值将达到 30.2 亿美元，到 2026 年将成长至 33.2 亿美元，到 2032 年将达到 60.5 亿美元，复合年增长率为 10.40%。

主要市场统计数据
基准年 2025 30.2亿美元
预计年份：2026年 33.2亿美元
预测年份：2032年 60.5亿美元
复合年增长率 (%) 10.40%

引言：强调精准罕见疾病诊断在改善患者预后和塑造未来医疗保健策略方面发挥的关键作用。

罕见疾病的诊断是现代医学中最具挑战性但也最有意义的领域之一，它需要精准、灵活和协作。这些疾病的症状往往不明显或不典型，很容易被常规诊断方法忽略。因此，及时准确地识别这些疾病不仅对于启动改变生活的治疗至关重要，而且对于减轻患者及其家庭的情绪和经济负担也至关重要。

分析改变罕见疾病诊断方法和缩短准确检测时间的变革性技术和监管变化。

罕见疾病诊断领域正经历着翻天覆地的变革，这主要得益于技术突破的整合和法规结构的不断改进。实验室服务正从单基因检测转向整合基因组学、蛋白质组学和代谢体学资料流的综合性多组体学平台。这种转变使临床医生能够超越症状评估，进行分子层面的诊断，从而指导标靶治疗。

评估 2025 年美国关税变化对罕见疾病诊断供应链和成本结构的影响。

美国2025年实施的关税调整对罕见疾病诊断的整个供应链产生了显着的连锁反应，影响了成本结构和策略采购决策。关键试剂、客製化检测套组和专用设备的进口关税，进一步增加了製造商和检查室在努力维持服务价格合理性和营运柔软性的困难。

我们将透过按测试类型、技术、疾病类型和最终用户群体进行细分来挖掘见解，并推动罕见疾病诊断的策略重点。

从多个细分观点分析罕见疾病诊断市场，有助于釐清当前趋势和新兴机会。从生化、遗传、组织病理学、免疫和分子生物学等不同诊断方法来看，每种方法都针对不同的临床需求。生化检测仍是代谢性疾病的初步筛检手段，而标靶基因检测则用于单基因疾病的最终诊断。组织病理学评估在某些肿瘤和免疫性疾病中仍然至关重要，免疫检测则能快速揭示自体免疫特征。分子技术展现出高灵敏度和特异性，尤其适用于需要多重检测的疾病。

为了发现罕见疾病诊断领域的成长机会，我们将分析美洲、欧洲、中东和非洲以及亚太地区的区域趋势。

了解区域趋势对于制定能够发挥本地优势并应对独特挑战的策略至关重要。在美洲，先进的医疗基础设施、健全的保险报销体系和雄厚的资本市场为尖端诊断技术的快速应用提供了支援。学术机构和私人企业之间的合作网络进一步加速了转化研究和临床检验。

我们确定了在罕见疾病诊断领域塑造创新伙伴关係和竞争策略的主要企业。

一群开拓型企业正透过对研发的策略性投资、全球扩张和合作项目，重塑罕见疾病诊断生态系统。产业领导企业正在拓展产品系列，建构整合平台，整合高解析度检体、自动化样本处理和先进的生物资讯技术。这些综合解决方案能够简化检查室工作流程，并以前所未有的速度记录具有临床应用价值的见解。

为产业领导者提供切实可行的建议，以加强合作、利用新技术并优化罕见疾病诊断结果。

致力于加速罕见疾病诊断进展的产业领导者应采取多管齐下的策略，并专注于合作、技术应用和相关人员参与。与学术机构、病患权益组织和政府机构建立跨部门合作关係，可以整合分散的专业知识，并促进标准化通讯协定达成共识。

详细的调查方法概述了资料收集和分析框架以及检验过程，这些框架和过程有助于深入了解罕见疾病诊断。

本研究采用一套全面的调查方法，旨在确保研究的严谨性、透明度和可操作性。主要数据是透过对诊断实验室、医院系统、监管机构和患者权益倡导团体的基层专业人员进行深度访谈收集的。这些访谈提供了观点，包括未满足的临床需求、技术应用挑战和监管的考量。

一个令人信服的结论，总结了核心发现、产业影响和策略挑战，用于提高罕见疾病诊断能力。

总而言之，罕见疾病诊断的发展得益于先进技术、不断完善的监管体係以及协作生态系统，使其处于科学创新与病患福祉的交汇点。细分市场分析揭示了具体的成长路径，而区域性洞察则强调了利用基础设施优势并解决特定障碍的在地化策略的重要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：罕见疾病诊断市场：依检测类型划分

  • 生物化学检验
  • 基因检测
  • 组织病理学检查
  • 免疫学检测
  • 分子检测

第九章：罕见疾病诊断市场：依技术划分

  • 萤光原位杂合反应（FISH）
  • 质谱分析
  • 下一代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 桑格定序
  • 全EXOME定序
  • 全基因组定序

第十章：罕见疾病诊断市场：依疾病类型划分

  • 心血管疾病
  • 血液疾病
  • 免疫系统疾病
  • 代谢性疾病
  • 神经系统疾病
  • 肿瘤性疾病
  • 呼吸系统疾病

第十一章 罕见疾病诊断市场：依最终用户划分

  • 诊断检测实验室
  • 医院和诊所
  • 实验室和合约研究组织

第十二章：罕见疾病诊断市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：罕见疾病诊断市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 罕见疾病诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国罕见疾病诊断市场

第十六章：中国罕见疾病诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 23andMe Inc.
  • 3billion, Inc.
  • Agilent Technologies Inc.
  • Ambry Genetics
  • ARCHIMED Life Science GmbH
  • ARUP Laboratories
  • AstraZeneca PLC
  • Azenta Life Sciences
  • Baylor Genetics
  • Bio-Rad Laboratories
  • Caris Life Sciences
  • Centogene AG
  • CENTOGENE NV
  • Eurofins Scientific Inc.
  • F. Hoffmann-La Roche Ltd.
  • Fulgent Genetics, Inc.
  • Illumina, Inc.
  • Invitae Corporation
  • MedGenome Labs Ltd
  • Novartis AG
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Quest Diagnostics Incorporated
  • Sanofi SA
  • Thermo Fisher Scientific Inc.
  • Travere Therapeutics Inc.
Product Code: MRR-5C6F41F5B034

The Rare Disease Diagnostics Market was valued at USD 3.02 billion in 2025 and is projected to grow to USD 3.32 billion in 2026, with a CAGR of 10.40%, reaching USD 6.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.02 billion
Estimated Year [2026] USD 3.32 billion
Forecast Year [2032] USD 6.05 billion
CAGR (%) 10.40%

Introduction Highlighting the Critical Role of Precise Rare Disease Diagnostics in Improving Patient Outcomes and Shaping Future Healthcare Strategies

Rare disease diagnostics represent one of the most challenging yet rewarding frontiers in modern healthcare, demanding precision, agility, and collaboration. These conditions often present with subtle or atypical symptoms that can elude standard diagnostic pathways. As such, timely and accurate identification is essential not only for initiating life-altering treatment but also for alleviating the emotional and financial burden experienced by patients and their families.

Over the past decade, advances in both laboratory science and digital technologies have transformed our ability to detect and characterize rare conditions. Next-generation sequencing and advanced imaging modalities now offer unprecedented resolution and throughput, while integrated data platforms facilitate deeper insights into genotype-phenotype correlations. In parallel, patient registries and real-world evidence networks fuel longitudinal studies that validate diagnostic algorithms and enhance our understanding of natural histories.

Looking ahead, the importance of rare disease diagnostics will only intensify as personalized medicine gains traction. Precision-driven approaches require not just isolated tests but cohesive diagnostic ecosystems that integrate modular platforms with artificial intelligence and machine learning to refine clinical decision support. These convergent trends underscore the critical role of diagnostics in shaping the future of healthcare strategy and underscore the urgent need for stakeholders to align around a common vision for innovation, efficiency, and patient impact.

Analyzing the Transformative Technological and Regulatory Shifts Redefining Rare Disease Diagnostic Approaches and Accelerating Time to Accurate Detection

The landscape of rare disease diagnostics is undergoing a profound metamorphosis driven by converging technological breakthroughs and evolving regulatory frameworks. Laboratories are transitioning from single-gene assays to comprehensive multi-omics platforms that combine genomic, proteomic, and metabolomic data streams. This shift enables clinicians to move beyond symptomatic assessments and toward molecularly informed diagnoses that can be linked to targeted therapies.

Simultaneously, regulatory agencies are streamlining pathways for breakthrough diagnostics, offering expedited review processes and adaptive protocols that prioritize rapid patient access. Harmonization efforts across jurisdictions are reducing duplicative documentation requirements, fostering global trials, and encouraging collaborative validation studies. As a result, diagnostic developers can navigate complex regulatory environments with greater predictability and speed.

Digital health innovations are further amplifying these transformative shifts. Cloud-based bioinformatics pipelines, decentralized clinical trial models, and telepathology solutions break down geographical barriers, enabling expert interpretation of complex rare disease profiles irrespective of patient location. Collectively, these trends are redefining how diagnostics are designed, validated, and deployed, ultimately accelerating the journey from discovery to clinical application and paving the way for a new era of precision healthcare.

Assessing the Impact of United States Tariff Changes in 2025 on the Landscape of Rare Disease Diagnostics Supply Chains and Cost Structures

The implementation of revised United States tariffs in 2025 has generated notable reverberations throughout the rare disease diagnostics supply chain, influencing both cost structures and strategic sourcing decisions. Import duties on key reagents, custom test kits, and specialized instrumentation have introduced additional layers of complexity for manufacturers and laboratories striving to maintain service affordability and operational flexibility.

In response, organizations are reevaluating supplier portfolios, seeking to diversify procurement channels and establish regional manufacturing hubs that mitigate exposure to fluctuating tariff schedules. Some diagnostic developers have accelerated partnerships with domestic component producers to secure preferential trade classifications and optimize landed costs. Meanwhile, distributors are renegotiating supply contracts to incorporate tariff escalation clauses, protecting margins while preserving service continuity for end users.

Despite the initial cost pressures, these adjustments have also spurred innovation in reagent formulation and assay consolidation. By engineering multi-analyte platforms that maximize throughput from a single sample input, laboratories can offset incremental duties through enhanced efficiency gains. Moreover, the tariff environment has underscored the strategic importance of proactive policy engagement and trade advocacy, empowering stakeholders to shape future tariff reviews and ensure sustainable access to cutting-edge diagnostic technologies.

Unveiling Insights from Test Type Technology Disease Type and End-User Segmentations to Drive Strategic Priorities in Rare Disease Diagnostics

Differentiating the rare disease diagnostics market through multiple segmentation lenses provides clarity around both current dynamics and emerging opportunities. When viewed through the prism of test type-which encompasses biochemical, genetic, histopathological, immunological, and molecular approaches-it becomes evident that each modality addresses distinct clinical imperatives. Biochemical assays continue to serve as frontline screens for metabolic disorders, while targeted genetic tests offer definitive confirmation of monogenic conditions. Histopathological evaluations remain indispensable for certain oncological and immunological disorders, and immunoassays provide rapid insights into autoimmune profiles. Molecular techniques deliver high sensitivity and specificity, especially for conditions requiring multiplexed detection.

Examining the market by technology-ranging from fluorescence in situ hybridization and mass spectrometry to advanced sequencing applications like next-generation, Sanger, whole exome, and whole genome sequencing-reveals an accelerating shift toward high-throughput platforms. These technologies facilitate comprehensive variant calling and enable the discovery of novel biomarkers.

Segmenting by disease type, from cardiovascular and neurological disorders to hematological, immunological, metabolic, oncological, and respiratory conditions, highlights the differential adoption rates and unmet needs within each therapeutic area. Furthermore, analyzing end-user categories-including diagnostic laboratories, hospitals and clinics, and research laboratories and contract research organizations-uncovers varying levels of investment in specialized instrumentation and data analytics capabilities. Together, these segmentation insights illuminate targeted pathways for market entry, resource allocation, and technology deployment.

Exploring Regional Dynamics across the Americas Europe Middle East Africa and Asia Pacific to Identify Growth Opportunities in Rare Disease Diagnostics

Understanding regional dynamics is essential for tailoring strategies that harness local strengths and address unique challenges. In the Americas, advanced healthcare infrastructure, robust reimbursement frameworks, and deep capital markets support rapid adoption of cutting-edge diagnostics. Collaborative networks between academic centers and commercial entities further accelerate translational research and clinical validation.

In Europe, Middle East and Africa, diverse regulatory landscapes coexist with ambitious initiatives aimed at harmonizing diagnostic standards across national borders. Pan-regional consortia facilitate shared access to biobanks and patient registries, while public-private partnerships have emerged to fund innovative assay development. Conversely, certain markets within the Middle East and Africa face infrastructure and training constraints that require targeted capacity-building investments.

Across Asia Pacific, government-led programs are driving domestic manufacturing of diagnostic reagents and instruments, complemented by widespread adoption of digital health solutions. Telemedicine platforms and remote interpretation services are bridging gaps in specialist availability, particularly in emerging markets. Strategic alliances between local companies and global technology providers are expanding the reach of advanced testing capabilities, while at the same time fostering regulatory knowledge transfer and workforce development.

Identifying Key Industry Players Shaping Innovation Partnerships and Competitive Strategies within the Rare Disease Diagnostics Sector

A cadre of pioneering companies is shaping the rare disease diagnostics ecosystem through strategic investments in research and development, global expansion, and collaborative ventures. Industry leaders are extending their product portfolios to encompass integrated platforms that combine high-resolution sequencing with automated sample processing and advanced bioinformatics. These holistic solutions streamline laboratory workflows while delivering clinically actionable insights with unprecedented speed.

Emerging players are carving out niches by focusing on bespoke assay development for ultra-rare conditions or leveraging artificial intelligence to interpret complex genomic datasets. Partnerships between diagnostic innovators and pharmaceutical firms are enabling companion diagnostic programs that align test development with therapeutic pipelines. Meanwhile, alliances with academic institutions and patient advocacy groups are fueling co-creation models that ensure diagnostic designs resonate with real-world clinical needs.

Competitive differentiation is increasingly driven by vertical integration, whereby stakeholders control multiple stages of the value chain-from reagent synthesis through data analytics and result interpretation. As a result, the most successful organizations are those that can orchestrate cross-functional teams to deliver end-to-end diagnostic services, fostering sustained leadership in the rapidly evolving rare disease diagnostics sector.

Actionable Recommendations for Industry Leaders to Enhance Collaboration Leverage Emerging Technologies and Optimize Rare Disease Diagnostic Outcomes

Industry leaders seeking to accelerate progress in rare disease diagnostics should embrace a multifaceted strategy focused on collaboration, technology adoption, and stakeholder engagement. Establishing cross-sector alliances with academic centers, patient advocacy organizations, and government agencies will unify fragmented expertise and drive consensus on standardized protocols.

Investing in modular, scalable platforms that accommodate both targeted panels and broad-spectrum analyses will ensure flexibility to address diverse clinical scenarios. Simultaneously, integrating artificial intelligence and machine learning into diagnostic pipelines can optimize data interpretation, reduce turnaround times, and enhance diagnostic confidence.

Engaging proactively with payers and regulatory bodies through value demonstration studies and real-world evidence generation will facilitate favorable reimbursement and approval pathways. Strengthening supply chain resilience by diversifying suppliers and building regional manufacturing capabilities can mitigate the impact of trade fluctuations. Finally, cultivating a patient-centric approach-incorporating patient feedback loops and transparent communication-will foster trust and improve uptake of novel diagnostic solutions.

Detailed Research Methodology Demonstrating Data Collection Analytical Frameworks and Validation Processes Underpinning Rare Disease Diagnostics Insights

This research integrates a comprehensive methodology designed to ensure rigor, transparency, and actionable insight. Primary data was collected through in-depth interviews with leading experts across diagnostic laboratories, hospital systems, regulatory agencies, and patient advocacy groups. These conversations provided nuanced perspectives on unmet clinical needs, technology adoption challenges, and regulatory considerations.

Secondary research encompassed an extensive review of peer-reviewed literature, clinical trial registries, patent filings, and governmental policy documents to validate emerging trends and technological breakthroughs. Publicly available financial reports and corporate disclosures were analyzed to track strategic investments, partnerships, and market entry activities.

A structured analytical framework was applied to triangulate qualitative insights with quantitative data, facilitating a balanced evaluation of market dynamics. Key findings underwent peer review by an internal advisory board, ensuring methodological consistency and eliminating bias. The resulting report offers a robust foundation for strategic decision-making, combining empirical evidence with expert interpretation.

Compelling Conclusion Summarizing Core Insights Industry Implications and Strategic Imperatives for Advancing Rare Disease Diagnostic Capabilities

In summary, rare disease diagnostics stands at the nexus of scientific innovation and patient impact, driven by advanced technologies, regulatory evolution, and collaborative ecosystems. Segmentation analysis reveals targeted pathways for growth, while regional insights underscore the importance of localized strategies that leverage infrastructure strengths and address specific barriers.

The recalibration of supply chains in response to tariff adjustments highlights both the vulnerabilities and the resilience of the diagnostics ecosystem. Industry leaders and emerging players alike must adopt agile business models that integrate scalable platforms, artificial intelligence, and patient-centric design to maintain a competitive edge.

By implementing the actionable recommendations outlined herein-fostering cross-sector collaborations, engaging proactively with stakeholders, and investing in modular technologies-organizations can enhance diagnostic precision, reduce time to diagnosis, and ultimately transform the patient journey. The collective pursuit of these strategic imperatives will accelerate the realization of a truly precision-driven era in rare disease diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rare Disease Diagnostics Market, by Test type

  • 8.1. Biochemical Tests
  • 8.2. Genetic Tests
  • 8.3. Histopathological Tests
  • 8.4. Immunological Tests
  • 8.5. Molecular Tests

9. Rare Disease Diagnostics Market, by Technology

  • 9.1. Fluorescence in situ Hybridization (FISH)
  • 9.2. Mass Spectrometry
  • 9.3. Next-Generation Sequencing (NGS)
  • 9.4. Polymerase Chain Reaction (PCR)
  • 9.5. Sanger Sequencing
  • 9.6. Whole Exome Sequencing
  • 9.7. Whole Genome Sequencing

10. Rare Disease Diagnostics Market, by Disease Type

  • 10.1. Cardiovascular Disorders
  • 10.2. Hematological Disorders
  • 10.3. Immunological Disorders
  • 10.4. Metabolic Disorders
  • 10.5. Neurological Disorders
  • 10.6. Oncological Disorders
  • 10.7. Respiratory Disorders

11. Rare Disease Diagnostics Market, by End-User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals & Clinics
  • 11.3. Research Laboratories & CROs

12. Rare Disease Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rare Disease Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rare Disease Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rare Disease Diagnostics Market

16. China Rare Disease Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 23andMe Inc.
  • 17.6. 3billion, Inc.
  • 17.7. Agilent Technologies Inc.
  • 17.8. Ambry Genetics
  • 17.9. ARCHIMED Life Science GmbH
  • 17.10. ARUP Laboratories
  • 17.11. AstraZeneca PLC
  • 17.12. Azenta Life Sciences
  • 17.13. Baylor Genetics
  • 17.14. Bio-Rad Laboratories
  • 17.15. Caris Life Sciences
  • 17.16. Centogene AG
  • 17.17. CENTOGENE N.V.
  • 17.18. Eurofins Scientific Inc.
  • 17.19. F. Hoffmann-La Roche Ltd.
  • 17.20. Fulgent Genetics, Inc.
  • 17.21. Illumina, Inc.
  • 17.22. Invitae Corporation
  • 17.23. MedGenome Labs Ltd
  • 17.24. Novartis AG
  • 17.25. OPKO Health, Inc.
  • 17.26. Pfizer Inc.
  • 17.27. Quest Diagnostics Incorporated
  • 17.28. Sanofi S.A.
  • 17.29. Thermo Fisher Scientific Inc.
  • 17.30. Travere Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 119. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. GCC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. NATO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)